Trial Profile
An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Ezabenlimab (Primary) ; Miptenalimab (Primary)
- Indications Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 30 Mar 2024 Results assessing safety, maximum tolerated dose (MTD), pharmacokinetics and antitumour activity of ezabenlimab in Study 1381.1 (NCT02952248), Study 1381.4 (NCT03433898) and Study 1381.3 (NCT03780725) published in the Cancer Immunology Immunotherapy.
- 27 Jul 2023 Status changed from active, no longer recruiting to completed.
- 10 Jul 2023 Planned End Date changed from 4 Aug 2023 to 19 Jul 2023.